XinYue Wang, William J. Jowsey, Chen-Yi Cheung, Caitlan J. Smart, Hannah R. Klaus, Noon EJ Seeto, Natalie JE Waller, Michael T. Chrisp, Amanda L. Peterson, Boatema Ofori-Anyinam, Emily Strong, Brunda Nijagal, Nicholas P. West, Jason H. Yang, Peter C. Fineran, Gregory M. Cook, Simon A. Jackson, Matthew B. McNeil
{"title":"Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis","authors":"XinYue Wang, William J. Jowsey, Chen-Yi Cheung, Caitlan J. Smart, Hannah R. Klaus, Noon EJ Seeto, Natalie JE Waller, Michael T. Chrisp, Amanda L. Peterson, Boatema Ofori-Anyinam, Emily Strong, Brunda Nijagal, Nicholas P. West, Jason H. Yang, Peter C. Fineran, Gregory M. Cook, Simon A. Jackson, Matthew B. McNeil","doi":"10.1038/s41467-024-54072-w","DOIUrl":null,"url":null,"abstract":"<p>Drug-resistant strains of <i>Mycobacterium tuberculosis</i> are a major global health problem. Resistance to the front-line antibiotic isoniazid is often associated with mutations in the <i>katG</i>-encoded bifunctional catalase-peroxidase. We hypothesise that perturbed KatG activity would generate collateral vulnerabilities in isoniazid-resistant <i>katG</i> mutants, providing potential pathway targets to combat isoniazid resistance. Whole genome CRISPRi screens, transcriptomics, and metabolomics were used to generate a genome-wide map of cellular vulnerabilities in an isoniazid-resistant <i>katG</i> mutant strain of <i>M. tuberculosis</i>. Here, we show that metabolic and transcriptional remodelling compensates for the loss of KatG but in doing so generates vulnerabilities in respiration, ribosome biogenesis, and nucleotide and amino acid metabolism. Importantly, these vulnerabilities are more sensitive to inhibition in an isoniazid-resistant <i>katG</i> mutant and translated to clinical isolates. This work highlights how changes in the physiology of drug-resistant strains generates druggable vulnerabilities that can be exploited to improve clinical outcomes.</p>","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"34 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-024-54072-w","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Drug-resistant strains of Mycobacterium tuberculosis are a major global health problem. Resistance to the front-line antibiotic isoniazid is often associated with mutations in the katG-encoded bifunctional catalase-peroxidase. We hypothesise that perturbed KatG activity would generate collateral vulnerabilities in isoniazid-resistant katG mutants, providing potential pathway targets to combat isoniazid resistance. Whole genome CRISPRi screens, transcriptomics, and metabolomics were used to generate a genome-wide map of cellular vulnerabilities in an isoniazid-resistant katG mutant strain of M. tuberculosis. Here, we show that metabolic and transcriptional remodelling compensates for the loss of KatG but in doing so generates vulnerabilities in respiration, ribosome biogenesis, and nucleotide and amino acid metabolism. Importantly, these vulnerabilities are more sensitive to inhibition in an isoniazid-resistant katG mutant and translated to clinical isolates. This work highlights how changes in the physiology of drug-resistant strains generates druggable vulnerabilities that can be exploited to improve clinical outcomes.
期刊介绍:
Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.